Navigation Links
Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
Date:5/15/2008

LAUSANNE, Switzerland, May 15 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced the signature of a license agreement with its long-term European pharmaceutical partner, for the marketing of Salvacyl(R)/Moapar(R) 3-month formulation, a gonadotropin releasing hormone (GnRH) agonist analogue, effective in the treatment of severe sexual deviations in adult men by inducing and maintaining a reversible reduction of testosterone to castrate serum levels. Debiopharm has developed and received marketing authorisations for Salvacyl / Moapar in nine major European countries, including France, Germany, UK, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland.

"There is a genuine unmet medical and social need for the treatment of sexual deviations. Not many pharma companies are willing or courageous enough to provide this type of treatment but we feel that we have a responsibility to help doctors and patients with the tools they need, even if it is difficult or controversial," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

About Salvacyl(R)/Moapar(R)

In the treatment of sexual deviations in men, administration of Salvacyl(R)/Moapar(R) every 3 months is an advantage over daily oral forms or intra-muscular weekly injections required with antiandrogens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) and there are fewer side effects.

Two studies have shown that regular injections of the active ingredient, triptorelin, over a period of eight months to seven years in male patients with sexual deviations demonstrated a good efficacy and safety profile. Triptorelin produced reversible serum castrate testosterone levels (defined as less than or equal to 1.735 nmol/L) in all patients, and concurrently with the decrease in testosterone levels, triptorelin treatment reduced deviant sexual behaviours in 35/36 patients with severe sexual deviations.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts

Kim Bill

VP, Corporate Development

Tel.: +41(0)21-321-01-11

Fax: +41(0)21-321-01-69

kbill@debiopharm.com

Additional Media Contacts

In London

Maitland

Brian Hudspith

Tel: +44(0)20-7379-5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Debiopharm and EPFL Establish an Oncology Chair
2. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
3. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
4. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
5. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
6. Quintiles Signs Agreement to Acquire Eidetics
7. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
8. Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
9. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
10. DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
11. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... ... August 10, 2017 , ... CNA Finance Chief ... initiated coverage on Next Group Holdings, Inc. and see's significant opportunity in the ... those that cannot engage in traditional banking services. According to industry estimates, approximately ...
(Date:8/10/2017)... BioLife Solutions , Inc. (NASDAQ: BLFS ), ... grade cell and tissue hypothermic storage and ... today reported operational highlights and financial results for the ... Revenue from biopreservation media product sales reached a ... of 2017, an increase of 29% over the same ...
(Date:8/8/2017)... ... August 08, 2017 , ... ... Trade Show Virtual Event, will discuss Phase Analysis Light Scattering (PALS) and ... method can be used to assess vaccine product quality and consistency regarding particle ...
(Date:8/8/2017)... ... ... Myoderm , a global clinical trial drug supply specialist, today announced the ... heels of the opening of Myoderm’s European warehouse facility earlier this year. As the ... establishing operations to support its customers around the world. , Andy Shepard joins ...
Breaking Biology Technology:
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
Breaking Biology News(10 mins):